What does YARO PRECLINICAL CONSULTING do?

YARO PRECLINICAL CONSULTING is registered with the CBE as active in: Vervaardiging van farmaceutische grondstoffen. Private Limited, started on 22 April 2008, 1 establishment.

What is the address of YARO PRECLINICAL CONSULTING?

The registered office of YARO PRECLINICAL CONSULTING is located at Lindekensstraat 35 box 5, 2300 Turnhout.

Is YARO PRECLINICAL CONSULTING still active?

Yes. According to the CBE (31 October 2026) YARO PRECLINICAL CONSULTING is active, legal situation “Normale toestand”, started on 22 April 2008.

Is YARO PRECLINICAL CONSULTING registered on Peppol?

Yes, YARO PRECLINICAL CONSULTING is registered on the Peppol network with ID 0208:0897435882.

What is the enterprise number of YARO PRECLINICAL CONSULTING?

The enterprise number of YARO PRECLINICAL CONSULTING is BE0897435882.

When was YARO PRECLINICAL CONSULTING founded?

YARO PRECLINICAL CONSULTING was founded on 22 April 2008.

Who are the directors of YARO PRECLINICAL CONSULTING?

According to the 2025 annual accounts, the directors of YARO PRECLINICAL CONSULTING are: Roland De Coster.

Is YARO PRECLINICAL CONSULTING a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 April 2008; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did YARO PRECLINICAL CONSULTING make in 2025?

YARO PRECLINICAL CONSULTING posted a profit after taxes of € 7,591 in financial year 2025.

What is the revenue of YARO PRECLINICAL CONSULTING?

As a small company, YARO PRECLINICAL CONSULTING is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 18,022.

YARO PRECLINICAL CONSULTING (Private Limited) - Turnhout

Dossier YARO PRECLINICAL CONSULTING, printed on 31 October 2026 from databakkes.be/en/0897435882/yaro-preclinical-consulting. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

YARO PRECLINICAL CONSULTING from Turnhout, company number BE0897435882, closed financial year 2025 with a result of € 7,591 after tax. For that financial year YARO PRECLINICAL CONSULTING recorded a gross margin of € 18,022 and equity of € 157,418. Compared with financial year 2024, the result moved from € 7,511 to € 7,591. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on January 30, 2026.

What it is worth Growing

€ 157,418

▲ 5% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 7,591

▲ 1% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 93,196

▲ 19% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 145,018.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 4,593

▼ 54% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 61

▼ 93% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 969

▲ 159% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 19,947 Gross margin 2022: € 19,947 First fiscal year in the series	€ 19,418 Gross margin 2023: € 19,418 ▼ 3% vs 2022 (€ 19,947) Unfavourable step	€ 19,179 Gross margin 2024: € 19,179 ▼ 1% vs 2023 (€ 19,418) Unfavourable step	€ 18,022 Gross margin 2025: € 18,022 ▼ 6% vs 2024 (€ 19,179) Unfavourable step	▼ 6%
Profit after taxes	€ 6,934 Profit after taxes 2022: € 6,934 First fiscal year in the series	€ 7,907 Profit after taxes 2023: € 7,907 ▲ 14% vs 2022 (€ 6,934) Favourable step	€ 7,511 Profit after taxes 2024: € 7,511 ▼ 5% vs 2023 (€ 7,907) Unfavourable step	€ 7,591 Profit after taxes 2025: € 7,591 ▲ 1% vs 2024 (€ 7,511) Favourable step	▲ 1%
Equity	€ 134,408 Equity 2022: € 134,408 First fiscal year in the series	€ 142,315 Equity 2023: € 142,315 ▲ 6% vs 2022 (€ 134,408) Favourable step	€ 149,826 Equity 2024: € 149,826 ▲ 5% vs 2023 (€ 142,315) Favourable step	€ 157,418 Equity 2025: € 157,418 ▲ 5% vs 2024 (€ 149,826) Favourable step	▲ 5%
Total debts	€ 5,663 Total debts 2022: € 5,663 First fiscal year in the series	€ 746 Total debts 2023: € 746 ▼ 87% vs 2022 (€ 5,663) Favourable step	€ 1,311 Total debts 2024: € 1,311 ▲ 76% vs 2023 (€ 746) Unfavourable step	€ 1,064 Total debts 2025: € 1,064 ▼ 19% vs 2024 (€ 1,311) Favourable step	▼ 19%
Cash	€ 59,959 Cash 2022: € 59,959 First fiscal year in the series	€ 66,313 Cash 2023: € 66,313 ▲ 11% vs 2022 (€ 59,959) Favourable step	€ 78,599 Cash 2024: € 78,599 ▲ 19% vs 2023 (€ 66,313) Favourable step	€ 93,196 Cash 2025: € 93,196 ▲ 19% vs 2024 (€ 78,599) Favourable step	▲ 19%
Retained profit	€ 122,008 Retained profit 2022: € 122,008 First fiscal year in the series	€ 129,915 Retained profit 2023: € 129,915 ▲ 6% vs 2022 (€ 122,008) Favourable step	€ 137,426 Retained profit 2024: € 137,426 ▲ 6% vs 2023 (€ 129,915) Favourable step	€ 145,018 Retained profit 2025: € 145,018 ▲ 6% vs 2024 (€ 137,426) Favourable step	▲ 6%
Balance sheet total	€ 140,071 Balance sheet total 2022: € 140,071 First fiscal year in the series	€ 143,061 Balance sheet total 2023: € 143,061 ▲ 2% vs 2022 (€ 140,071) Unchanged	€ 151,138 Balance sheet total 2024: € 151,138 ▲ 6% vs 2023 (€ 143,061) Unchanged	€ 158,481 Balance sheet total 2025: € 158,481 ▲ 5% vs 2024 (€ 151,138) Unchanged	▲ 5%

Key figures of YARO PRECLINICAL CONSULTING, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to YARO PRECLINICAL CONSULTING?

What happened at YARO PRECLINICAL CONSULTING in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 30, 2026 New annual accounts for financial year 2025: profit of € 7,591 (▲ 1% vs 2024). Source: NBB ↗
Apr 22, 2008 New establishment in Turnhout. KBO
2008 Roland De Coster became a director. NBB
Apr 22, 2008 Start of the company according to the CBE. KBO

In short

From € 6,934 profit in 2022 to € 7,591 profit in 2025.

Paid € 21,574 in corporate taxes since 2022.

Best year ever: 2023, with € 7,907 profit.

Original PDFs at the National Bank ↗

Management

Roland De Coster

YARO PRECLINICAL CONSULTING

Behind YARO PRECLINICAL CONSULTING is Roland De Coster.

Directors

According to the 2025 annual accounts

Roland De Coster

Director

since 2008

Establishments

Establishment units

Physical locations of this company

Registered office

Lindekensstraat 35 box 5

2300 Turnhout

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0897.435.882

VAT number

BE 0897.435.882

Registered office

Lindekensstraat 35 bus 5, 2300 Turnhout

Names & denominations

YARO PRECLINICAL CONSULTING

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

22 April 2008

Peppol

Active · Active since 24 Oct 2025

Activities · NACE

Vervaardiging van farmaceutische grondstoffen

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige zakelijke dienstverlening, neg

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

YARO PRECLINICAL CONSULTING

Financials

What happened to YARO PRECLINICAL CONSULTING?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions